Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass.

Jansen R, Moehlendick B, Bartenhagen C, Tóth C, Lehwald N, Stoecklein NH, Knoefel WT, Lachenmayer A.

Sci Rep. 2018 Jul 13;8(1):10637. doi: 10.1038/s41598-018-28941-6.

PMID:
30006612
2.

Design and implementation of an electromagnetic ultrasound-based navigation technique for laparoscopic ablation of liver tumors.

Paolucci I, Schwalbe M, Prevost GA, Lachenmayer A, Candinas D, Weber S, Tinguely P.

Surg Endosc. 2018 Jul;32(7):3410-3419. doi: 10.1007/s00464-018-6088-1. Epub 2018 Feb 12.

PMID:
29435744
3.

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Llovet JM, Villanueva A, Lachenmayer A, Finn RS.

Nat Rev Clin Oncol. 2015 Aug;12(8):436. doi: 10.1038/nrclinonc.2015.121. Epub 2015 Jun 23. No abstract available.

PMID:
26099984
4.

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Llovet JM, Villanueva A, Lachenmayer A, Finn RS.

Nat Rev Clin Oncol. 2015 Jul;12(7):408-24. doi: 10.1038/nrclinonc.2015.103. Epub 2015 Jun 9. Review. Erratum in: Nat Rev Clin Oncol. 2015 Aug;12(8):436.

PMID:
26054909
5.

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM.

Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.

6.

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma.

Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, SenBanerjee S, Ukomadu C, Llovet JM, Sadler KC.

Cancer Cell. 2014 Feb 10;25(2):196-209. doi: 10.1016/j.ccr.2014.01.003. Epub 2014 Jan 30.

7.

Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.

Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM, Powers S.

Gastroenterology. 2013 Dec;145(6):1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055. Epub 2013 Sep 5.

8.

Notch 1 tumor expression is lacking in highly proliferative pancreatic neuroendocrine tumors.

Krausch M, Kroepil F, Lehwald N, Lachenmayer A, Schott M, Anlauf M, Cupisti K, Knoefel WT, Raffel A.

Endocrine. 2013 Aug;44(1):182-6. doi: 10.1007/s12020-012-9850-5. Epub 2012 Dec 7.

PMID:
23225326
9.

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.

Clin Cancer Res. 2012 Sep 15;18(18):4997-5007. Epub 2012 Jul 18.

10.

Trends in adrenal surgery: institutional review of 528 consecutive adrenalectomies.

Lachenmayer A, Cupisti K, Wolf A, Raffel A, Schott M, Willenberg HS, Eisenberger CF, Knoefel WT.

Langenbecks Arch Surg. 2012 Oct;397(7):1099-107. doi: 10.1007/s00423-012-0973-1. Epub 2012 Jun 22.

PMID:
22722636
11.

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM.

J Hepatol. 2012 Jun;56(6):1343-50. doi: 10.1016/j.jhep.2012.01.009. Epub 2012 Feb 6.

12.

Diagnostic and prognostic molecular markers in hepatocellular carcinoma.

Mínguez B, Lachenmayer A.

Dis Markers. 2011;31(3):181-90. doi: 10.3233/DMA-2011-0841. Review.

13.

Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2011 Dec;55(6):1325-31. doi: 10.1016/j.jhep.2011.02.034. Epub 2011 Apr 13.

14.

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM.

Gastroenterology. 2011 May;140(5):1618-28.e16. doi: 10.1053/j.gastro.2011.02.009. Epub 2011 Feb 13.

15.

New strategies in hepatocellular carcinoma: genomic prognostic markers.

Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM.

Clin Cancer Res. 2010 Oct 1;16(19):4688-94. doi: 10.1158/1078-0432.CCR-09-1811. Epub 2010 Aug 16.

16.

Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma.

Lachenmayer A, Hoshida Y, Llovet JM.

Gastroenterology. 2010 Aug;139(2):692-4. doi: 10.1053/j.gastro.2010.06.036. Epub 2010 Jun 25. No abstract available.

17.

Molecular approaches to treatment of hepatocellular carcinoma.

Lachenmayer A, Alsinet C, Chang CY, Llovet JM.

Dig Liver Dis. 2010 Jul;42 Suppl 3:S264-72. doi: 10.1016/S1590-8658(10)60515-4. Review.

18.

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM.

Semin Liver Dis. 2010 Feb;30(1):35-51. doi: 10.1055/s-0030-1247131. Epub 2010 Feb 19. Review.

19.

Superficial soft tissue sarcomas of the extremities and trunk.

Lachenmayer A, Yang Q, Eisenberger CF, Boelke E, Poremba C, Heinecke A, Ohmann C, Knoefel WT, Peiper M.

World J Surg. 2009 Aug;33(8):1641-9. doi: 10.1007/s00268-009-0051-1.

PMID:
19430830
20.

Nestin as a marker in the classification of adrenocortical tumors.

Lachenmayer A, Lichtenauer UD, Cox T, Schott M, Malendowicz LK, Goretzki PE, Cupisti K, Scherbaum WA, Bornstein SR, Willenberg HS.

Horm Metab Res. 2009 May;41(5):397-401. doi: 10.1055/s-0029-1202788. Epub 2009 Mar 17.

PMID:
19294612

Supplemental Content

Loading ...
Support Center